Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 42.5
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of SION is 42 and suggests 1% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decrea
Data is available to registered users only
Buy
Sell